High-impact non-sponsored symposia announced for Florence

6543
The WCO-IOF-ESCEO’17 intensive four-day scientific programme will be enhanced by sixteen topical non-sponsored symposia, with participation by top experts in the field.

The WCO-IOF-ESCEO ’17, the world’s largest congress in the musculoskeletal field, features an extensive scientific programme. This week, sixteen non-sponsored symposia, led by top speakers, have been announced. The one-hour symposia will present the latest developments in a specific areas of expertise - allowing time for discussion and interaction. 

Below is a complete list of the planned non-sponsored symposia to help you begin planning your personal agenda for the 4-day Congress.

NON-SPONSORED SYMPOSIA

FRIDAY MARCH 24 - 8:00-9:00

Bone health: A reflection of the social mosaic
Chair: G. Duque

  • Medieval evidence: Reconstructing social status from British Medieval skeletons, J. Miszkiewicz
  • Contemporary evidence: Social gradient of osteoporosis, S. Brennan‑Olsen
  • Epigenetic evidence: Chronic stress, inflammatory response and osteoporosis risk, J. Riancho
  • Moderated panel & audience questions

Fracture risk assessment to target treatment: Effectiveness and cost-utility
Chairs: J.A. Kanis, J. Cauley

  • Innovations in Approach to absolute risk assessment, C. Cooper
  • Prospective RCTs to evaluate effectiveness of such strategies, M.R. McClung
  • Economic Consequences of Treatment on basis of fracture risk assessment, E. McCloskey

Can exercise counter inflammation in the aged?
Chair: I. Bautmans

  • Immunosenescence and impact of exercise on cellular markers, H. Cao Dinh
  • Chronic low-grade inflammation and effects of exercise, K. Liberman
  • Anti-inflammatory effects of resistance training: dose-response relationship, L. Nuvagah Forti

Diagnosis and Management of Fibrous dysplasia / McCune Albright syndrome: A global patient pathway
Chair: M.L. Brandi

  • Introduction and Mission Statement of the International Consortium, K. Javaid
  • Pathophysiology of skeletal and extra-skeletal manifestations of FD/MAS,  N. Hamdy
  • Consensus Clinical Care Pathway, K. Javaid
  • Therapeutic options in FD/MAS (including surgical, skeletal & endocrine; current & future), R. D. Chapurlat
  • Panel Discussion

Global differences in dietary calcium intake
Chair: B. Dawson‑Hughes

  • Introduction : including the role of calcium in bone growth and preservation, B. Dawson‑Hughes
  • Presentation of the Calcium Map results. E. Balk
  • Presentation on the skeletal consequences of inadequate calcium intake., P. R. Ebeling

SATURDAY MARCH 25 - 8:00-9:00

Osteosarcopenia: a practical approach for the prevention of falls and osteoporotic fractures
Chair: G. Duque

  • Introduction, G Duque
  • Clinical and biochemical phenotype of osteosarcopenia, A. Frisoli
  • Musculoskeletal imaging and osteosarcopenia, N. Binkley
  • Therapeutic interventions for osteosarcopenia. G. Duque
  • Questions & Answers

How can exercise counter muscle weakness in the aged?
Chair: I. Bautmans

  • Muscle weakness and fatigue: does the type of contraction matter? L. De Dobbeleer
  • Can exercise counter muscle activation deficits? P. Arnold
  • Strength gain and functional benefits of resistance training: dose-response relationship, E. Van Roie

Closing the gap in the assessment of quality of life in sarcopenia
Chairs: O. Bruyère, F. Landi

  • Importance of patient-centred outcomes » (PCOs) in the assessment of chronic disorders, F. Cerreta
  • Assessment of quality of life in sarcopenia: what can we learn from osteoporosis? R. Rizzoli
  • SarQoL: a validated tool for the assessment of quality of life in sarcopenia, C. Beaudart

Chronic Imuno-inflammation and bone structure
Chairs: O. D. Messina, C. A. F. Zerbini

  • Introduction – Inflammation and bone structure, C. A. F. Zerbini
  • Quantification and Impact of Secondary Osteoarthritis using HR-pQCT in Anti-citrullinated protein antibody Rheumatoid Arthritis Patients, C. Figueiredo
  • Bone impairment assessed using HR-pQCT and vertebral fractures in juvenile systemic lupus erythematosus, R. M. Pereira
  • Discussion, O.D. Messina

Long-Term Therapy - Clinical Practice Cavaets
Chairs: B. Muzzi Camargos

  • Treatment Evidences Beyond 5 years, O. Rosero Olarte
  • Treatment failure, L. Fernando Vidal Neira
  • Bone Imaging and Biochemical Monitoring on Long-Term Treated Patients, B. Muzzi Camargos
  • What happens after stopping denosumab? M. Belen Zanchetta

Parental influences on offspring bone: Multidisciplinary evidence
Chair: S. Brennan‑Olsen

  • Introduction to symposium session, S. Brennan‑Olsen
  • Life-course epidemiology: Developmental Origins of Health and Disease, N. Hyde
  • Animal models: Adverse conditions in utero and bone, T. Romano
  • Public health: Health literacy, role modelling and prevention, S. Hosking
  • Moderated panel discussion, & audience questions

SUNDAY MARCH 26 - 8:00-9:00

Cortical Porosity and Trabecular Bone Score: Are both important?
Chair: E. McCloskey

  • Skeletal determinants of fracture risk – can we do better? E. McCloskey
  • Role of cortical porosity in fracture risk and potential implication for clinical practice, E. Seeman
  • Role of trabecular bone Score in fracture risk and use in clinical routine, N. Binkley

Osteoporosis management in the Balkan countries
Chair: S. Sokolovic

  • Opening remarks, S. Sokolovic
  • Osteoporosis diagnosis and management in Serbia, A. Dimic
  • Osteoporosis diagnosis and management in Turkey, U. Akarirmak
  • Management of the silent disease in Romania, A. Ildiko Gasparik
  • Strategy for the treatment of osteoporosis in Greece: the ELECOST paradigm, G. Lyritis
  • Osteoporosis diagnosis and management in Bosnia and Herzegovina, S. Sokolovic
  • Closing remarks

Osteoporosis in Turkey: National osteoporosis prevention health programs by The Turkish Osteoporosis Society
Chairs: O. Peker, S. Oncel

  • Welcome and introductions, O. Peker & S. Oncel
  • Current Status of Osteoporosis in Turkey, O. El
  • Prevention of Osteoporotic Fractures in Turkey: Similarities and Differences with Europ, F. Calis
  • Male Osteoporosis: Turkish Data, Y. Gokce Kutsal
  • Presentation of an epidemiological study named TUR-BOR-OS, Y. Kirazli

Lipids and Bone: The Role of Fatty Acid Amides
Chair: S. Silverman

  • Fatty Acids and Bone Biology: An Overview, S. Silverman
  • Fatty Acyl Amides as Novel Therapeutics for the Treatment of Osteoporosis, J. Tam
  • Cannabidiol enhances fracture healing by targeting collagen crosslinking, Y. Gabet

Assessment and management of sarcopenia : The Liège experience
Chairs: J. Petermans, O. Bruyère

  • Sarcopenia in community dwelling subjects: the SarcoPhAge study, C. Beaudart
  • Sarcopenia in nursing home residents : the SENIOR cohort, F. Buckinx
  • Nutritional needs of sarcopenic patients : a study using indirect calorimetry in a geriatric unit, S. Allepaerts

View the complete WCO-IOF-ESCEO '17 scientific programme

 

Tag: